News

The data reported significant improvements in serum urate (sUA) following 12 weeks of treatment.

Results from the MUST trial reported that ustekinumab monotherapy was just as effective in treating psoriatic arthritis as treatment with ustekinumab plus methotrexate.

Although patients with inflammatory conditions reported positive attitudes towards biologic treatment, they were far less familiar with biosimilars, indicating the need for clinicians to provide patient education more effectively.

Given the growing evidence that patients with gout are at an increased risk of developing cardiovascular disease, accurately screening patients and identifying potential risk factors is of critical importance.

Released on January 3, the American College of Physician's living osteoporosis guideline represents the organization's first update on the topic since 2017 and includes 6 specific recommendations for pharmacologic management of osteoporosis or low bone mass.

At the 6-month mark, there were no significant differences between the treatment groups regarding composite score-defined remission.

It is well-known that rheumatoid arthritis patients have a heightened risk of cardiovascular events, but how do RA treatments affect this risk? Test your knowledge with this quiz.

A group of investigators, researchers and policymakers discuss the issues, innovations and aspirations that may define 2023 advances.

Take a few minutes to review the most noteworthy studies published on Rheumatology Network in 2022.

Alfredo Aguirre, MD, discusses the latest data regarding lupus this year at the American College of Rheumatology (ACR) Convergence 2022, trends in lupus management, and the importance of remission in lupus.

Ayman Askari, MD, discusses the recent trends in rheumatoid arthritis, studies presented at the American College of Rheumatology (ACR) Convergence 2022, and the pressing issues that face rheumatologists moving into 2023.

Current literature is trending towards exploring the impact of complementary and alternative treatments for fibromyalgia and an overall focus on multidisciplinary care.

Take 5 minutes to catch up on Rheumatology Network's top articles from December 2022.

Theodore Fields, MD, FACP, discusses the most important gout studies in 2022, regulatory news, and the most pressing issues surrounding gout moving into 2023.

Potential barriers to an interest in pediatric rheumatology include inadequate exposure and mentorship within these specialties, as well as long periods of required training and lower compensation for pediatric specialists.

With a great deal of marginalized patients navigating burdensome, chronic, heterogenetic disease today, rheumatologists are becoming more invested in what the individual needs and wants from care.

The results imply the possibility of improving patient stratification based on both clinical and immune cellular phenotypes.

Announced by Radius Health on December 20, the US FDA approval for abaloparatide (Tymlos) indicates the agent as a treatment to increase bone density in men with osteoporosis at high risk of fracture or in patients who have failed or are intolerant to other available osteoporosis therapy.

Fibromyalgia syndrome and connective tissue disorders were found to be highly associated in terms of both prevalence and symptoms.

What does the American College of Rheumatology recommend regarding discontinuing DMARD therapy in patients with rheumatoid arthritis? Test your knowledge with this quiz.

A comparative trial of biologic agents suggest IL-17A inhibitors may more significantly improve skin clearance in comorbid patients.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending December 17, 2022.

The results suggest a basis for clinicians to detect the earlier potential development of psoriasis, psoriatic arthritis, and Crohn’s disease.

Self-evidence can help rheumatic autoimmune disease patients gain control of symptoms when the standard of care fails them.

The percentage of patients with fibromyalgia experiencing alexithymia was substantially higher when compared with healthy controls and was linked to pain and psychological distress.

Beginning January 1, 2023, all new content and insights from the editorial teams of Rheumatology Network, Practical Cardiology and Endocrinology Network will be hosted on HCPLive.Com.

How do you assess if a patient with rheumatoid arthritis is in remission, and how should treatment be tapered for patients in remission? Test your knowledge with this quiz

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending December 10, 2022.

"Fibromyalgia is best managed as a chronic condition, with non-pharmacological therapies as the primary treatment and medications as an adjunct to symptom relief.”

Enrollment in the FIT Teens program, which began in January 2018, was paused in March 2020 to revise operations manuals, conduct remote treatment sessions to evaluate accuracy and fidelity, obtain regulatory approvals, and train staff on the new procedures.